CheckMate 017和057五年随访:纳武利尤单抗对比多西他赛治疗经治晚期非小细胞肺癌
该分析汇总CheckMate 017和057两项III期随机试验,比较纳武利尤单抗与多西他赛在经治晚期非小细胞肺癌中的五年疗效与安全性。结果显示纳武利尤单抗五年总生存率13.4% vs 2.6%,无进展生存率8.0% vs 0%,未见新安全性信号。
要点
- 纳武利尤单抗五年OS率13.4%,多西他赛2.6%,显示持续生存获益。
- 五年PFS率纳武利尤单抗8.0%,多西他赛0%。
- 2年和3年无进展患者后续5年生存概率分别为82.0%和93.0%。
核心结论
- 五年随访时纳武利尤单抗对比多西他赛持续显示生存获益,OS率提高约五倍,无新安全性信号。
研究设计与样本
- 汇总CheckMate 017和057两项III期随机试验,共854例经治晚期NSCLC患者,1:1随机接受纳武利尤单抗(3 mg/kg 每2周)或多西他赛(75 mg/m2 每3周)。
主要发现
- CheckMate 017和057最短随访分别为64.2和64.5个月时,纳武利尤单抗组50例、多西他赛组9例存活。
- 五年汇总OS率分别为13.4% vs 2.6%,五年PFS率分别为8.0% vs 0%。
- 纳武利尤单抗组2年和3年无进展患者5年生存概率分别为82.0%和93.0%,5年仍无进展概率分别为59.6%和78.3%。
- 3-5年随访期间31例纳武利尤单抗治疗患者中8例(25.8%)报告治疗相关不良事件,其中7例为新发事件,1例(3.2%)为3级,无4级事件。
临床怎么用
- 经治晚期NSCLC患者使用纳武利尤单抗可获得长期生存获益,五年随访支持其作为标准治疗选择。
- 长期随访中需关注迟发性治疗相关不良事件,但未见新安全性信号。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Immunotherapy has revolutionized the treatment of advanced non-small-cell lung cancer (NSCLC). In two phase III trials (CheckMate 017 and CheckMate 057), nivolumab showed an improvement in overall survival (OS) and favorable safety versus docetaxel in patients with previously treated, advanced squamous and nonsquamous NSCLC, respectively. We report 5-year pooled efficacy and safety from these trials. METHODS: Patients (N = 854; CheckMate 017/057 pooled) with advanced NSCLC, ECOG PS ≤ 1, and progression during or after first-line platinum-based chemotherapy were randomly assigned 1:1 to nivolumab (3 mg/kg once every 2 weeks) or docetaxel (75 mg/m2 once every 3 weeks) until progression or unacceptable toxicity. The primary end point for both trials was OS; secondary end points included progression-free survival (PFS) and safety. Exploratory landmark analyses were investigated. RESULTS: After the minimum follow-up of 64.2 and 64.5 months for CheckMate 017 and 057, respectively, 50 nivolumab-treated patients and nine docetaxel-treated patients were alive. Five-year pooled OS rates were 13.4% versus 2.6%, respectively; 5-year PFS rates were 8.0% versus 0%, respectively. Nivolumab-treated patients without disease progression at 2 and 3 years had an 82.0% and 93.0% chance of survival, respectively, and a 59.6% and 78.3% chance of remaining progression-free at 5 years, respectively. Treatment-related adverse events (TRAEs) were reported in 8 of 31 (25.8%) nivolumab-treated patients between 3-5 years of follow-up, seven of whom experienced new events; one (3.2%) TRAE was grade 3, and there were no grade 4 TRAEs. CONCLUSION: At 5 years, nivolumab continued to demonstrate a survival benefit versus docetaxel, exhibiting a five-fold increase in OS rate, with no new safety signals. These data represent the first report of 5-year outcomes from randomized phase III trials of a programmed death-1 inhibitor in previously treated, advanced NSCLC.
引用
- Borghaei H, Gettinger S, Vokes EE, et al. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. J Clin Oncol. 2021. PMID: 33449799. doi:10.1200/JCO.20.01605
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。